Is wilms tumor a candidate neoplasia for treatment with wnt/β-catenin pathway modulators?-A report from the renal tumors biology-driven drug development workshop

Daniela Perotti, Peter Hohenstein, Italia Bongarzone, Mariana Maschietto, Mark Weeks, Paolo Radice, Kathy Pritchard-Jones

Research output: Contribution to journalArticle

Abstract

The European Network for Cancer Research in Children and Adolescents consortium organized a workshop in Rome, in June 2012, on "Biology-Driven Drug Development Renal Tumors Workshop" to discuss the current knowledge in pediatric renal cancers and to recommend directions for further research. Wilms tumor is the most common renal tumor of childhood and represents a success of pediatric oncology, with cure rates of more than 85% of cases. However, a substantial minority (~25%) responds poorly to current therapies and requires "high-risk" treatment or relapse. Moreover, the successfully treated majority are vulnerable to the late effects of treatment, with nearly one quarter reporting severe chronic health conditions by 25 years of follow-up. Main purposes of this meeting were to advance our understanding on the molecular drivers in Wilms tumor, their heterogeneity and interdependencies; to provide updates on the clinical-pathologic associations with biomarkers; to identify eligible populations for targeted drugs; and to model opportunities to use preclinical model systems and prioritize targeted agents for early phase clinical trials. At least three different pathways are involved in Wilms tumor; this review represents the outcome of the workshop discussion on the WNT/b-catenin pathway in Wilms tumorigenesis.

Original languageEnglish
Pages (from-to)2619-2627
Number of pages9
JournalMolecular Cancer Therapeutics
Volume12
Issue number12
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Catenins
Wnt Signaling Pathway
Wilms Tumor
Kidney
Education
Pharmaceutical Preparations
Pediatrics
Neoplasms
Kidney Neoplasms
Research
Carcinogenesis
Therapeutics
Biomarkers
Clinical Trials
Recurrence
Health
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Is wilms tumor a candidate neoplasia for treatment with wnt/β-catenin pathway modulators?-A report from the renal tumors biology-driven drug development workshop. / Perotti, Daniela; Hohenstein, Peter; Bongarzone, Italia; Maschietto, Mariana; Weeks, Mark; Radice, Paolo; Pritchard-Jones, Kathy.

In: Molecular Cancer Therapeutics, Vol. 12, No. 12, 12.2013, p. 2619-2627.

Research output: Contribution to journalArticle

@article{5b4082cd5a284e45beca5aeca9d20dbe,
title = "Is wilms tumor a candidate neoplasia for treatment with wnt/β-catenin pathway modulators?-A report from the renal tumors biology-driven drug development workshop",
abstract = "The European Network for Cancer Research in Children and Adolescents consortium organized a workshop in Rome, in June 2012, on {"}Biology-Driven Drug Development Renal Tumors Workshop{"} to discuss the current knowledge in pediatric renal cancers and to recommend directions for further research. Wilms tumor is the most common renal tumor of childhood and represents a success of pediatric oncology, with cure rates of more than 85{\%} of cases. However, a substantial minority (~25{\%}) responds poorly to current therapies and requires {"}high-risk{"} treatment or relapse. Moreover, the successfully treated majority are vulnerable to the late effects of treatment, with nearly one quarter reporting severe chronic health conditions by 25 years of follow-up. Main purposes of this meeting were to advance our understanding on the molecular drivers in Wilms tumor, their heterogeneity and interdependencies; to provide updates on the clinical-pathologic associations with biomarkers; to identify eligible populations for targeted drugs; and to model opportunities to use preclinical model systems and prioritize targeted agents for early phase clinical trials. At least three different pathways are involved in Wilms tumor; this review represents the outcome of the workshop discussion on the WNT/b-catenin pathway in Wilms tumorigenesis.",
author = "Daniela Perotti and Peter Hohenstein and Italia Bongarzone and Mariana Maschietto and Mark Weeks and Paolo Radice and Kathy Pritchard-Jones",
year = "2013",
month = "12",
doi = "10.1158/1535-7163.MCT-13-0335",
language = "English",
volume = "12",
pages = "2619--2627",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Is wilms tumor a candidate neoplasia for treatment with wnt/β-catenin pathway modulators?-A report from the renal tumors biology-driven drug development workshop

AU - Perotti, Daniela

AU - Hohenstein, Peter

AU - Bongarzone, Italia

AU - Maschietto, Mariana

AU - Weeks, Mark

AU - Radice, Paolo

AU - Pritchard-Jones, Kathy

PY - 2013/12

Y1 - 2013/12

N2 - The European Network for Cancer Research in Children and Adolescents consortium organized a workshop in Rome, in June 2012, on "Biology-Driven Drug Development Renal Tumors Workshop" to discuss the current knowledge in pediatric renal cancers and to recommend directions for further research. Wilms tumor is the most common renal tumor of childhood and represents a success of pediatric oncology, with cure rates of more than 85% of cases. However, a substantial minority (~25%) responds poorly to current therapies and requires "high-risk" treatment or relapse. Moreover, the successfully treated majority are vulnerable to the late effects of treatment, with nearly one quarter reporting severe chronic health conditions by 25 years of follow-up. Main purposes of this meeting were to advance our understanding on the molecular drivers in Wilms tumor, their heterogeneity and interdependencies; to provide updates on the clinical-pathologic associations with biomarkers; to identify eligible populations for targeted drugs; and to model opportunities to use preclinical model systems and prioritize targeted agents for early phase clinical trials. At least three different pathways are involved in Wilms tumor; this review represents the outcome of the workshop discussion on the WNT/b-catenin pathway in Wilms tumorigenesis.

AB - The European Network for Cancer Research in Children and Adolescents consortium organized a workshop in Rome, in June 2012, on "Biology-Driven Drug Development Renal Tumors Workshop" to discuss the current knowledge in pediatric renal cancers and to recommend directions for further research. Wilms tumor is the most common renal tumor of childhood and represents a success of pediatric oncology, with cure rates of more than 85% of cases. However, a substantial minority (~25%) responds poorly to current therapies and requires "high-risk" treatment or relapse. Moreover, the successfully treated majority are vulnerable to the late effects of treatment, with nearly one quarter reporting severe chronic health conditions by 25 years of follow-up. Main purposes of this meeting were to advance our understanding on the molecular drivers in Wilms tumor, their heterogeneity and interdependencies; to provide updates on the clinical-pathologic associations with biomarkers; to identify eligible populations for targeted drugs; and to model opportunities to use preclinical model systems and prioritize targeted agents for early phase clinical trials. At least three different pathways are involved in Wilms tumor; this review represents the outcome of the workshop discussion on the WNT/b-catenin pathway in Wilms tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=84890518697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890518697&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-13-0335

DO - 10.1158/1535-7163.MCT-13-0335

M3 - Article

C2 - 24258344

AN - SCOPUS:84890518697

VL - 12

SP - 2619

EP - 2627

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -